ID

43404

Description

ODM derived from http://clinicaltrials.gov/show/NCT00682396

Lien

http://clinicaltrials.gov/show/NCT00682396

Mots-clés

Versions (3)
  1. 09/12/2013 09/12/2013 - Martin Dugas
  2. 15/04/2014 15/04/2014 - Julian Varghese
  3. 20/09/2021 20/09/2021 -
Téléchargé le

20 septembre 2021

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility NCT00682396 Myelodysplastic Syndrome

Allemand Anglais
Détails

Eligibility

1 Formulaires  
  1. StudyEvent: Eligibility
    1. Eligibility
Inclusion Criteria
age 18 Years to 65 Years
Disease: cytologically proven
primary or therapy related myelodysplastic syndrome (MDS) either as
refractory anaemia (RA) according FAB or RA with or without dysplasia according WHO
refractory anaemia with ringsideroblasts (RARS) according FAB or RARS with or without dysplasia according WHO
refractory anaemia with excess of blasts (RAEB) according FAB or RAEB I or RAEB II according WHO
refractory anaemia with excess of blast in transformation (RAEB-T) according FAB
CMML (dysplastic type) according WHO
Secondary Acute Myeloid Leukemia
Blast count <20 percent in bone marrow with or without chemotherapy at time of transplantation
Patient eligible for standard and dose-reduced conditioning as per local guideline
Patient age 18-60 years if donor is a HLA-matched UNRELATED donor (HLA-A, HLA-B, HLA-DRB1 and HLA-DQB1) (one mismatch allowed)
Patient age 18-65 years if donor is a HLA-matched RELATED donor (HLA-A, HLA-B, HLA-DRB1 and HLA-DQB1)(one antigen-mismatch allowed)
no major organ dysfunction
written informed consent of the patient
Exclusion Criteria
Blasts >20% in bone marrow at time of transplantation
no written informed consent
Central nervous system (CNS) involvement status
Severe irreversible renal, hepatic, pulmonary or cardiac disease, such as
total bilirubin, SGPT or SGOT > 2 times upper the normal level
LVEF - Left ventricular ejection fraction
Creatinine clearance (CrCl) measurement
DLCO <35% and/or receiving supplementary continuous oxygen
Positive serology for HIV
pregnant or lactating women
patients with a life-expectancy of < 6 months because of another debilitating disease
serious psychiatric or psychological disorders
invasive fungal infection at time of registration
Retour au début de la page

Similar models

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial